drugset / Trial / NCT00208208

Geodon (Ziprasidone) for Posttraumatic Stress Disorder

NCT00208208

Phase 4 Completed 80 enrolled Creighton University Pfizer · collab
RandomizedParallel-groupDouble-blindDiagnostic

Summary

Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiveness of Geodon in civilian men and women who suffer from severe PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8).

Timeline

Start
2002-12
Primary completion
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule